Perspectives on Medical Reimbursement By JR Associates “Will my device be reimbursed?” This is one of the most important questions life sciences entrepreneurs must consider when developing new medical technology. But in today’s dynamic and complex healthcare environment, clear answers can be elusive. Harvard Innovation Lab recently invited our VP of Global Health Policy, Jo Ellen Slurzberg, to help clarify…
Perspectives on Medical Reimbursement By JR Associates Continuing its efforts to cultivate a marketplace of innovation that better serves those affected by autism, Autism Speaks recently hosted its third annual Autism Investment Conference in Boston. Our VP of Global Health Policy, Jo Ellen Slurzberg, was among the nearly 200 investors, entrepreneurs, healthcare advocates and corporate…
Perspectives on Medical Reimbursement By JR Associates When medical technology companies develop reimbursement strategies for the U.S. market, it’s a smart business move to look beyond this country’s borders. That’s the advice JR Associates VP of Global Health Policy, Jo Ellen Slurzberg shared in a recent interview with Medical Device Daily. Jo Ellen acknowledged that planning…
Perspectives on Medical Reimbursement By JR Associates Recently, the trade press and mainstream news have been paying a lot of attention to bundled payments. Stories have focused primarily on how this shift in medical reimbursement will affect patients, providers and payers. Payers and provider networks are creating internal systems to identify the cost of treating…
Perspectives on Medical Reimbursement Issues By JR Associates Whitepaper: Impact of ICD-10 on Coding and Reimbursement for Cardiac Rhythm Management Procedures Authors: • Beth Bontemps, MSN, RN, NP, CCS Senior Consultant, JR Associates, Inc. • Rayellen Gilles, Customer Experience, Wolters Kluwer Law & Business Summary: By October 1, 2013, all U.S. healthcare providers are required to…
Perspectives on Medical Reimbursement By JR Associates The path to advancements in disease detection and treatment is notoriously complex, circuitous and costly. However, even after FDA approval, there are no guarantees of reimbursement through CMS coverage. This is an essential lesson in the case of Eli Lilly’s Amyvid PET scan imaging agent, which is used…
Outsourcing Partner Speeds Entry Into Commercial Cancer Detection and Treatment Market Albuquerque, N.M. — (Business Wire), June 30, 2004 — Biomoda, Inc. announced today that it has contracted with reimbursement consulting firm, JR Associates, to help advance Biomoda’s patented biopharmaceutical products. Primarily, JR Associates consultants will investigate the potential for securing positive coverage, coding, and payment by Medicare and commercial…
